Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Up 55.3% in February

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, an increase of 55.3% from the February 13th total of 4,700 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 440,100 shares, the days-to-cover ratio is currently 0.0 days.

Enzon Pharmaceuticals Price Performance

Shares of ENZN stock traded up $0.00 during trading hours on Monday, hitting $0.10. The stock had a trading volume of 1,681 shares, compared to its average volume of 93,211. The stock has a market capitalization of $7.50 million, a price-to-earnings ratio of 10.11 and a beta of 0.26. Enzon Pharmaceuticals has a one year low of $0.06 and a one year high of $0.24. The stock’s 50-day moving average price is $0.13 and its two-hundred day moving average price is $0.12.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.